Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 1, 2013, Pages 34-42

  Yang, Jun ^a   Li, Xiaohui ^a,c   Al Lamki, Rafia S ^a   Wu, Changxin ^a   Weiss, Astrid ^b   Berk, Joachim ^b   Schermuly, Ralph T ^b   Morrell, Nicholas W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

BMP signaling pathway; cGKI; PDE5 inhibitor; pulmonary hypertension; smooth muscle cell

Indexed keywords

8 BROMO CYCLIC GMP; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 4; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; DNA BINDING PROTEIN; SILDENAFIL; SMAD1 PROTEIN; SMAD5 PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BINDING SITES; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; BONE MORPHOGENETIC PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASE TYPE I; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION, PULMONARY; INHIBITOR OF DIFFERENTIATION PROTEIN 1; MALE; MONOCROTALINE; MUSCLE, SMOOTH, VASCULAR; MUTATION; MYOCYTES, SMOOTH MUSCLE; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHORYLATION; PIPERAZINES; PROMOTER REGIONS, GENETIC; PULMONARY ARTERY; PURINES; RATS; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMAD1 PROTEIN; SMAD5 PROTEIN; SULFONES; TRANSFECTION; VASODILATOR AGENTS;

EID: 84871788547     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300121     Document Type: Article

References (26)

1. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, Zapol WM, Miyazono K, Li E, Bloch KD. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol. 2004;287:L1241-L1247.
2. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA III, Loyd JE, Nichols WC, Trembath RC, International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26:81-84.
3. Machado RD, Aldred MA, James V, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat. 2006;27:121-132.
4. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 2005;16:251-263.
5. Yang J, Davies RJ, Southwood M, Long L, Yang X, Sobolewski A, Upton PD, Trembath RC, Morrell NW. Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension. Circ Res. 2008;102:1212-1221.
6. Yang J, Li X, Al-Lamki RS, Southwood M, Zhao J, Lever AM, Grimminger F, Schermuly RT, Morrell NW. Smad-dependent and Smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ Res. 2010;107:252-262.
7. Klinger JR. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med. 2007;28:143-67, ix.
8. Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J. 2008;32:198-209.
9. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009;361:1864-1871.
10. Schwappacher R, Weiske J, Heining E, Ezerski V, Marom B, Henis YI, Huber O, Knaus P. Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity. EMBO J. 2009;28:1537-1550.
11. Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK, Morrell NW. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation. 2009;119:566-576.
12. Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, Atkinson C, Chen H, Trembath RC, Morrell NW. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res. 2005;96:1053-1063.
13. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811-2821.
14. Croom KF, Curran MP. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs. 2008;68:383-397.
15. Ito T, Ozawa K, Shimada K. Current drug targets and future therapy of pulmonary arterial hypertension. Curr Med Chem. 2007;14:719-733.
16. Kiliçkesmez K, Küçükoglu MS. Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension. Anadolu Kardiyol Derg. 2010;10(Suppl 2):16-18.
17. Zhao L, Sebkhi A, Ali O, Wojciak-Stothard B, Mamanova L, Yang Q, Wharton J, Wilkins MR. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J. 2009;34:948-957.
18. Thomas M, Docx C, Holmes AM, Beach S, Duggan N, England K, Leblanc C, Lebret C, Schindler F, Raza F, Walker C, Crosby A, Davies RJ, Morrell NW, Budd DC. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am J Pathol. 2009;174:380-389.
19. Sawada N, Itoh H, Chun TH, Tamura N, Yamashita J, Doi K, Tanaka T, Inoue M, Masatsugu K, Fukunaga Y, Saito T, Nakao K. Constitutively active form of cGMP-dependent protein kinase (cGK) 1 alpha suppresses vascular smooth muscle cell proliferation. J Hypertens. 1998;16:S102.
20. Markert T, Krenn V, Leebmann J, Walter U. High expression of the focal adhesion-and microfilament-associated protein VASP in vascular smooth muscle and endothelial cells of the intact human vessel wall. Basic Res Cardiol. 1996;91:337-343.
21. Schlossmann J, Feil R, Hofmann F. Signaling through NO and cGMP-dependent protein kinases. Ann Med. 2003;35:21-27.
22. Schlossmann J, Feil R, Hofmann F. Insights into cGMP signalling derived from cGMP kinase knockout mice. Front Biosci. 2005;10:1279-1289.
23. Kwak YL, Jones KA, Warner DO, Perkins WJ. NO responsiveness in pulmonary artery and airway smooth muscle: the role of cGMP regulation. Am J Physiol Lung Cell Mol Physiol. 2006;290:L200-L208.
24. Goligorsky MS, Noiri E, Tsukahara H, Budzikowski AS, Li H. A pivotal role of nitric oxide in endothelial cell dysfunction. Acta Physiol Scand. 2000;168:33-40.
25. Fellner SK, Arendshorst WJ. Complex interactions of NO/cGMP/PKG systems on Ca2+ signaling in afferent arteriolar vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2010;298:H144-H151.
26. Tsukahara H, Noiri E, Jiang MZ, Hiraoka M, Mayumi M. Role of nitric oxide in human pulmonary microvascular endothelial cell adhesion. Life Sci. 2000;67:1-11.